This week immunization experts from around the world will gather in Geneva to review new evidence and discuss recommendations for WHO immunization policy. An important item on the agenda for the fall meeting is typhoid vaccines. A recommendation on the use of new typhoid conjugate vaccines (TCVs) could significantly impact the effort to reduce the global burden of typhoid, a disease that impacts nearly 12 million people a year.

The flu poses a serious health risk for pregnant women and their babies. Due to changes in how the immune system, heart and lungs function during pregnancy, pregnant women are at higher risk of experiencing severe symptoms from influenza.

Last month, The Lancet published the 2016 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), the global health community’s annual look into mortality and morbidity for major diseases, injuries and other health risk factors wo

In South Asia, where the burden of enteric fever is thought to be highest, most typhoid studies have focused on urban areas. As a result, researchers have been unsure how well available data could be extrapolated to predominantly rural areas.

In September, the Bill and Melinda Gates Foundation released the inaugural “Goalkeepers” report – an annual update aimed at accelerating progress toward achieving the Sustainable Development Goals (SDGs). The report tracks 18 data points selected from the 244 indicators in the SDGs that are “fundamental to people’s health and wellbeing.”

New typhoid conjugate vaccines offer important advantages over prior vaccines, including the ability to protect young children, longer lasting protection, and the potential to be a part of routine immunization of infants.

Families across the United States are sending their young children back to school. School preparations are not limited to buying school supplies. Parents should make sure their children are up-to-date with vaccinations.

We launched the award-winning END7 campaign in 2012 to build a grassroots movement to end the seven most common neglected tropical diseases (NTDs). With your support, we mobilized funding to support programs that treated more than 50 million people, helped increase US and UK funding for NTDs and spread awareness of the global NTD burden. Now, five years later, we are concluding the END7 campaign. We are grateful for the support of all of our followers, student groups and generous donors who made the campaign such a success.

Investigators from the Aga Khan University (AKU) are actively investigating a large outbreak of typhoid fever bacteria that are resistant to ceftriaxone, an antibiotic commonly used by physicians to treat this infection.

Wendy Holman Joins Sabin Vaccine Institute Board of Trustees

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Wendy Commins Holman to its Board of Trustees. Ms. Holman is the CEO and founder of Ridgeback Biotherapeutics, a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases.

Pages